
The response of RECIST and GCIG CA125 to neoadjuvant chemotherapy for epithelial ovarian cancer should not be used as specific predictive markers to stratify patients who are likely to benefit from DPS but instead used in conjunction with the patient's clinical capacity to undergo cytoreductive surgery. A patient should not be refused surgery based only on the lack of a RECIST or GCIG CA125 response.
Like
Save
Share